Pharmaceutical imports into Iraq are subject to one of the most substantive sectoral frameworks within Iraqi trade regulation, reflecting the public health considerations engaged in the supply of pharmaceuticals and the substantial regulatory attention given to the sector internationally. The framework is administered principally by the Ministry of Health through the Iraqi Drug Registration system, with the State Company for Marketing Drugs and Medical Appliances (Kimadia) functioning as the principal state-owned pharmaceutical importer alongside private-sector pharmaceutical importers operating under sectoral licences. The framework engages the Pharmacy Practice Law, the Drug Control Law, sectoral instruments addressing specific categories of pharmaceuticals, and the broader regulatory framework.
Statutory Framework
The principal instruments governing pharmaceutical imports into Iraq are:
- The Pharmacy Practice Law, governing pharmaceutical practice and the regulation of pharmaceutical operations
- The Iraqi Drug Control Law and implementing instruments, governing narcotic and psychotropic substances
- Ministry of Health instruments establishing the Iraqi Drug Registration system and the framework for the registration and importation of pharmaceuticals
- The Public Health Law and broader sectoral framework
- The Customs Law No. 23 of 1984 and the Customs Tariff Law No. 22 of 2010 for the customs framework
- Iraq’s obligations under the international drug control conventions, including the Single Convention on Narcotic Drugs of 1961, the Convention on Psychotropic Substances of 1971, and the Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Iraqi Drug Registration
The Iraqi Drug Registration system is administered by the Ministry of Health through the relevant directorate. Pharmaceutical products to be imported into Iraq must, in general, be registered in the Iraqi Drug Registration system as a precondition to importation. The registration engages:
- Submission of comprehensive technical documentation establishing the safety, efficacy, and quality of the product
- Demonstration of registration in the country of origin and in major reference jurisdictions
- Evidence of compliance with current Good Manufacturing Practice (GMP) by the manufacturing facility
- Submission of representative product samples
- Submission of finished product specifications and analytical methods
- Provision of summary of product characteristics and patient information leaflets
- Pricing information for products subject to pricing controls
- Payment of the prescribed registration fees
- Review by the Iraqi Drug Registration committee
- Issuance of the registration certificate
The registration process engages substantial lead time, with implications for the planning of new product introductions into the Iraqi market. The registration is periodically renewable, with renewal subject to continued compliance with the registration framework.
Pharmaceutical Importer Licensing
Pharmaceutical importation into Iraq is conducted by licensed pharmaceutical importers operating under the framework of the Ministry of Health. The licensing engages:
- Commercial registration of the entity under the Companies Law No. 21 of 1997
- Specific authorisation as a pharmaceutical importer from the Ministry of Health
- Operational capability including qualified pharmaceutical personnel, suitable storage facilities, and adequate quality systems
- Cooperation with the Ministry of Health supervisory framework
- Compliance with the broader pharmaceutical practice framework
The licensing operates alongside the Commercial Agency Law No. 79 of 2017 framework for the importation of goods for trading purposes through registered commercial agents.
Kimadia
The State Company for Marketing Drugs and Medical Appliances (Kimadia / كيمادية) is the state-owned pharmaceutical entity functioning as the principal procurement and distribution entity for the public health sector in Iraq. Kimadia conducts substantial pharmaceutical importation supporting the supply of pharmaceuticals to public hospitals, primary care facilities, and the broader public health system. The framework engages Kimadia procurement procedures, tender frameworks, and contractual arrangements with international pharmaceutical suppliers. Private-sector pharmaceutical importers operate alongside Kimadia, principally serving the private healthcare sector and pharmacy distribution channels.
Good Manufacturing Practice
Compliance with current Good Manufacturing Practice (cGMP) is a substantive requirement for pharmaceutical manufacturers supplying the Iraqi market. The cGMP framework engages internationally recognised standards including those of the World Health Organization, the United States Food and Drug Administration, the European Medicines Agency, and the International Conference on Harmonisation. Evidence of cGMP compliance is, in general, required as part of the Iraqi Drug Registration application and may be verified through manufacturer inspections, third-party audit reports, and other documentation. Manufacturers without cGMP compliance face substantive challenges in achieving Iraqi registration for their products.
Controlled Substances
Controlled substances including narcotic drugs, psychotropic substances, and precursor chemicals engage a particularly substantive framework. The principal elements include:
- Specific authorisation for the importation of each consignment
- Importation only through licensed handlers
- Comprehensive documentation including international permits
- Secure storage and distribution arrangements
- Detailed record-keeping subject to inspection
- Compliance with the international drug control conventions
- Substantial penalties under the Drug Control Law and the Penal Code for unauthorised handling
Operators considering the handling of controlled substances should engage with the framework at an early stage, recognising the substantial procedural and substantive requirements engaged.
Biological Products and Cold Chain
Biological products, including vaccines, insulins, and biological therapeutics, engage specific considerations:
- Cold chain requirements throughout the supply chain, from manufacturer to point of use
- Temperature monitoring and documentation
- Specific shipping and transport arrangements
- Storage facilities meeting cold chain requirements
- Specific registration considerations reflecting the biological character of the products
- Stability and shelf-life considerations
Cold chain failures may render biological products unfit for use and engage substantial commercial and patient safety consequences. Importers of biological products should structure their supply chains with substantive attention to cold chain integrity.
Pharmaceutical Pricing
Pharmaceutical pricing in Iraq engages a framework supporting both accessibility and the sustainability of the pharmaceutical supply. The framework may include:
- Price registration as part of the drug registration process
- Reference pricing by comparison with international markets
- Periodic price reviews
- Specific arrangements for tendered pharmaceuticals supplied to the public sector through Kimadia
- Distribution margin arrangements affecting the pricing along the supply chain
Importers should engage with the pricing framework as part of the broader product registration and market entry strategy.
Inspection and Testing
Pharmaceutical imports are subject to inspection at the point of entry by the customs authority and by Ministry of Health inspectors. The inspection engages documentary review, physical inspection, and laboratory testing of samples. The testing supports the verification of the conformity of the imported product with its registered specifications and the absence of counterfeiting or substitution. Discrepancies identified at the inspection stage may result in detention of the consignment pending resolution, with potential consequences including release on satisfactory resolution, requirement for re-export, or destruction.
How We Can Help
Etihad Law Firm advises on pharmaceutical imports into Iraq, including the structuring of the Iraqi Drug Registration application, pharmaceutical importer licensing, GMP compliance documentation, controlled substances authorisations, biological product importation, Kimadia engagement for public sector supply, pricing structuring, response to inspection findings, and the conduct of disputes engaging pharmaceutical imports.